search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
POINT-OF-CARE TESTING


Blood gas breakthrough: haemolysis detection at the point of care


Werfen UK recently hosted its first Acute Care User Group Meeting, hearing from a knowledgeable line up of speakers as well as launching a groundbreaking update for its GEM range of blood gas analysers.


Birmingham was the venue for the first Acute Care User Group Meeting to be hosted by Werfen UK. A diverse but engaged audience – including many of Werfen’s own key opinion leaders – gathered at a city-centre hotel to hear from speakers on subjects including the clinical implications of pre analytical errors and haemolysis, gaining ISO:15189 accreditation for POCT services, implementation of the ROTEM thromboelastometry POCT system, and NHS procurement.


The event also served as a platform


for Werfen to formally present the latest addition to the company’s line up of blood gas analysers, the GEM Premier 7000 with iQM3. The new machine


builds on the success of the GEM 5000 with the new feature of offering haemolysis detection at the point of care for the first time.


Presentations After a welcome from Werfen UK’s General Manager Richard Hames, the


day’s first speaker was Dr Martin Myers, Joint Clinical Lead at NHSE Getting it Right First Time (GIRFT), Pathology; Laboratory Director Clinical Biochemistry and Clinical Lead for POCT at Lancashire Teaching Hospitals NHS Foundation Trust. Martin presented on the clinical implications of pre-analytical errors and haemolysis, kicking off with an explanation of how the GIRFT initiative works in practice, against a background of integrated pathology networks and improvement through regulation to deliver clinically led advancement with the patient at the centre. The GIRFT methodology was covered, starting with relevant data from all trusts and ending with the National Report, which highlighted best practices, concerns,


Feedback from the HCPs involved highlighted the instant feedback on sample quality, and the POCT team was able to identify operators with a high haemolysis rate


Dr Martin Myers, Joint Clinical Lead at NHSE Getting it Right First Time (GIRFT), Pathology. WWW.PATHOLOGYINPRACTICE.COM APRIL 2025 45


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56